文献速递免疫规划

靶向Fcγ受体的PspA融合蛋白疫苗在同种型特异性结局中的研究

Isotype-specific outcomes in Fc gamma receptor targeting of PspA using fusion proteins as a vaccination strategy against Streptococcus pneumoniae infection.
PubMed 文献 · Vaccine · 2020-07-07

本研究探讨以PspA与不同IgG亚类Fc段融合蛋白经黏膜免疫靶向Fcγ受体抗肺炎链球菌的效果。结果显示PspA-IgG2a Fc融合蛋白增强PspA特异性免疫应答并有效抵御黏膜Spn攻击,而PspA-IgG1 Fc融合蛋白因与抑制性FcγRIIB结合获益有限。FcγRIIB缺陷动物中IgG1融合蛋白保护效力显著增强。

要点

  • PspA-IgG2a Fc融合蛋白经黏膜免疫可增强Th1细胞因子及PspA特异性IgG和IgA。
  • PspA-IgG1 Fc融合蛋白因与抑制性FcγRIIB结合,较单用PspA获益有限。
  • FcγRIIB缺陷动物中IgG1融合蛋白保护效力显著增强,伴B细胞成熟与增殖增加。

核心结论

  • 靶向激活型FcγR的PspA-IgG2a Fc融合蛋白经黏膜免疫可诱导有效的细胞和体液免疫并抵御黏膜Spn攻击。
  • Fc同种型亚类显著影响免疫诱导的效应功能和致死性Spn攻击后的存活,选择Fc区域需审慎。
  • 关注FcγRIIB结合的Fc工程化是抗Spn感染的有价值疫苗策略。

研究设计与样本

  • 研究使用PspA与IgG2a Fc或IgG1 Fc融合的融合蛋白进行黏膜免疫,并在FcγRIIB缺陷动物中评估IgG1融合蛋白的保护效力。

主要发现

  • PspA-IgG2a Fc融合蛋白将肺泡巨噬细胞极化为AM1表型,增加肺内常规树突状细胞亚群,并增强Th1细胞因子及PspA特异性IgG和IgA。
  • PspA-IgG1 Fc融合蛋白较单用PspA获益有限,归因于与抑制性FcγRIIB的相互作用。
  • FcγRIIB缺陷动物中IgG1融合蛋白保护效力显著增强,伴B细胞成熟和增殖水平增加。

临床怎么用

  • 黏膜免疫中使用Fc融合蛋白靶向FcγR时,应审慎选择Fc同种型亚类以优化免疫效应功能。
  • Fc工程化关注FcγRIIB结合可作为抗Spn疫苗策略的开发方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Streptococcus pneumoniae (Spn) remains a considerable threat to public health despite the availability of antibiotics and polysaccharide conjugate vaccines. The lack of mucosal immunity in addition to capsular polysaccharide diversity, has proved to be problematic in developing a universal vaccine against Spn. Targeting antigen to Fc receptors is an attractive way to augment both innate and adaptive immunity against mucosal pathogens, by promoting interactions with activating Fcγ receptors (FcγR) that mediate diverse immunomodulatory functions. The effect of targeting FcγR is highly influenced by the IgG subclass, which bares differential affinities for activating and inhibitory FcγR. In the current study we demonstrate targeting activating FcγR with fusion proteins consisting of PspA and IgG2a Fc enhance PspA-specific immune responses, and effectively protect against mucosal Spn challenge. Specifically, targeting PspA to FcγR polarized alveolar macrophage to the AM1 phenotype and increased conventional dendritic cell subsets in the lung in addition to augmenting Th1 cytokines and PspA-specific IgG and IgA. In contrast, fusion proteins consisting of PspA fused to the IgG1 Fc provided minimal benefit over administration of PspA alone, as a result of interaction with the inhibitory FcγRIIB. Protective efficacy of the IgG1 fusion protein was significantly enhanced in animals deficient for FcγRIIB accompanied by increased B cell maturation and proliferation levels in these animals. These studies demonstrate FcγR targeting is an effective strategy for inducing potent cellular and humoral responses via mucosal immunization with Fc fusion proteins, however, careful consideration of the Fc region utilized is required since Fc isotype subclass heavily influenced immunization induced effector functions and survival against lethal Spn challenge. Fc-engineering with specific attention to FcγRIIB engagement presents a valuable vaccine strategy for protecting against Spn infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wiedinger K, McCauley J, Bitsaktsis C, et al. Isotype-specific outcomes in Fc gamma receptor targeting of PspA using fusion proteins as a vaccination strategy against Streptococcus pneumoniae infection. Vaccine. 2020. PMID: 32646816. doi:10.1016/j.vaccine.2020.06.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。